1 study found for:    23234632 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer;   Bone Metastases in Subjects With Advanced Breast Cancer;   Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: Genetic: AMG 162 180 mg (SC) q 12 weeks;   Drug: IV Bisphosphonate q 4 weeks;   Genetic: AMG 162- 180 mg q 4 weeks

Indicates status has not been verified in more than two years